Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – June 8, 2022 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call to Order**

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Stephen Anderson –	participating in person
Dr. Jennifer de los Angeles –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://zoom.us/webinar/register/WN_73z8ERX7Sv-KeQGP3GVqPg
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 952 7560 1667
Passcode: 69395211

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. April 13, 2022 DUR Board Meeting Minutes
   B. April 13, 2022 DUR Board Recommendations Memorandum
   C. May 11, 2022 DUR Board Meeting Minutes
   D. May 11, 2022 DUR Board Recommendations Memorandum
   E. Correspondence

Items to be presented by Dr. Chandler, Dr. Travers, Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/SoonerPsych and Pediatric SoonerPsych Antipsychotic Monitoring Program Update – See Appendix B**
   A. Pharmacy Helpdesk Activity for May 2022
   B. Medication Coverage Activity for May 2022
   C. SoonerPsych and Pediatric SoonerPsych Antipsychotic Monitoring Program Update

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

5. **Action Item – Approval of May 2022 DUR Board Recommendations – See Appendix C**
   A. Vote to Prior Authorize Releuko™ (Filgrastim-ayow) and Update the Approval Criteria for the Granulocyte Colony-Stimulating Factors (G-CSFs)
      i. Market News and Updates

ii. Cost Comparison for Filgrastim Products
iii. College of Pharmacy Recommendations

B. Vote to Prior Authorize Lampit® (Nifurtimox)
i. Market News and Updates
ii. Lampit® (Nifurtimox) Product Summary
iii. College of Pharmacy Recommendations

C. Vote to Prior Authorize Skytrofa® (Lonapegsomatropin-tcgd) and Voxzogo™ (Vosoritide) and Update the Approval Criteria for the Growth Hormone Products
i. Market News and Updates
ii. Product Summaries
iii. College of Pharmacy Recommendations

D. Vote to Prior Authorize Ponvory® (Ponesimod) and Update the Approval Criteria for the Multiple Sclerosis Medications
i. Market News and Updates
ii. Ponvory® (Ponesimod) Product Summary
iii. College of Pharmacy Recommendations

E. Vote to Prior Authorize Brexafemme® (Ibrexafungerp) and Update the Approval Criteria for the Systemic Antifungal Medications
i. Market News and Updates
ii. Brexafemme® (Ibrexafungerp) Product Summary
iii. College of Pharmacy Recommendations

F. Vote to Prior Authorize Zynlonta™ (Loncastuximab Tesirine) and Update the Approval Criteria for the Lymphoma Medications
i. Market News and Updates
ii. Zynlonta™ (Loncastuximab Tesirine) Product Summary
iii. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Ryaltris™ (Mometasone/Olopatadine Nasal Spray) and Update the Approval Criteria for the Nasal Allergy Medications – See Appendix D**

A. Market News and Updates
B. Ryaltris™ (Mometasone/Olopatadine) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Nexviazyme® (Avalglucosidase Alfa-ngpt) – See Appendix E**

A. Market News and Updates
B. Nexviazyme® (Avalglucosidase Alfa-ngpt) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

8. **Action Item – Vote to Prior Authorize Kerendia® (Finerenone), Rezvoglar™ (Insulin Glargine-aglr), and Semglee® (Insulin Glargine-yfgn) and Update the Approval Criteria for the Anti-Diabetic Medications – See Appendix F**
   A. Market News and Updates
   B. Kerendia® (Finerenone) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

9. **Action Item – Vote to Prior Authorize Exkivity® (Mobocertinib), Lumakras™ (Sotorasib), and Rybrevant™ (Amivantamab-vmjw) and Update the Approval Criteria for the Lung Cancer Medications – See Appendix G**
   A. Market News and Updates
   B. Product Summaries
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

10. **Annual Review of Genitourinary and Cervical/Endometrial Cancer Medications and 30-Day Notice to Prior Authorize Camcevi™ (Leuprolide), Pluvicto® (Lutetium Lu 177 Vipivotide Tetraxetan), Tivdak® (Tisotumab Vedotin-tfty) and Welireg™ (Belzutifan) – See Appendix H**
    A. Introduction
    B. Current Prior Authorization Criteria
    C. Utilization of Genitourinary and Cervical/Endometrial Cancer Medications
    D. Prior Authorization of Genitourinary and Cervical/Endometrial Cancer Medications
    E. Market News and Updates
    F. Product Summaries
    G. College of Pharmacy Recommendations
    H. Utilization Details of Genitourinary and Cervical/Endometrial Cancer Medications

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

11. **Annual Review of the SoonerCare Pharmacy Benefit – See Appendix I**
    A. Summary
    B. Medicaid Drug Rebate Program
    C. Alternative Payment Models
    D. Drug Approval Trends
    E. Traditional Versus Specialty Pharmacy Products
    F. Top 10 Traditional Therapeutic Classes by Reimbursement: Calendar Year 2021
    G. Top 10 Specialty Therapeutic Classes by Reimbursement: Calendar Year 2021
    H. Top 10 Medications by Reimbursement: Calendar Year 2021
    I. Cost Per Claim
    J. Market Projections
    K. Conclusion

L. Top 50 Reimbursed Drugs by Calendar Year
M. Top 50 Medications by Total Number of Claims: Calendar Year 2021
N. Top 10 Traditional and Specialty Therapeutic Categories by Calendar Year
O. Calendar Year Age Group Comparison

Items to be presented by Dr. Travers, Dr. Muchmore, Chairman:

12. Annual Review of Attention-Deficit/Hyperactivity Disorder (ADHD) and Narcolepsy Medications and 30-Day Notice to Prior Authorize Xelstrym™ (Dextroamphetamine Transdermal System) – See Appendix J

A. Current Prior Authorization Criteria
B. Utilization of ADHD and Narcolepsy Medications
C. Prior Authorization of ADHD and Narcolepsy Medications
D. Oklahoma Resources
E. Market News and Updates
F. College of Pharmacy Recommendations
G. Utilization Details of ADHD and Narcolepsy Medications

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

13. Annual Review of Antiviral Medications and 30-Day Notice to Prior Authorize Livtencity™ (Maribavir) – See Appendix K

A. Current Prior Authorization Criteria
B. Utilization of Antiviral Medications
C. Prior Authorization of Antiviral Medications
D. Market News and Updates
E. Livtencity™ (Maribavir) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Antiviral Medications

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

14. Annual Review of Insomnia Medications and 30-Day Notice to Prior Authorize Quviviq™ (Daridorexant) – See Appendix L

A. Current Prior Authorization Criteria
B. Utilization of Insomnia Medications
C. Prior Authorization of Insomnia Medications
D. Market News and Updates
E. Quviviq™ (Daridorexant) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Insomnia Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

15. Annual Review of Atypical Antipsychotic Medications and 30-Day Notice to Prior Authorize Invega Hafyera™ (Paliperidone Palmitate Injection) – See Appendix M

A. Current Prior Authorization Criteria
B. Utilization of Atypical Antipsychotic Medications

C. Prior Authorization of Atypical Antipsychotic Medications
D. Oklahoma Resources
E. Market News and Updates
F. Invega Hafyera™ (Paliperidone Palmitate Injection) Product Summary
G. College of Pharmacy Recommendations
H. Utilization Details of Atypical Antipsychotic Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

16. **30-Day Notice to Prior Authorize Ryplazim® (Plasminogen, Human-tvmh) – See Appendix N**

A. Introduction
B. Ryplazim® (Plasminogen, Human-tvmh) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

17. **Annual Review of Various Special Formulations and 30-Day Notice to Prior Authorize Citalopram Capsule, Dartisla ODT™ (Glycopyrrolate Orally Disintegrating Tablet), Fleqsuvy™ (Baclofen Oral Suspension), Lofena™ (Diclofenac Potassium Tablet), Loreev XR™ (Lorazepam Extended-Release Capsule), Norliqva® (Amlodipine Besylate Oral Solution), Seglentis® (Celecoxib/Tramadol Tablet), Sutab® (Sodium Sulfate/Magnesium Sulfate/Potassium Chloride Tablet), Tarpeyo™ (Budesonide Delayed-Release Capsule), Vuity™ (Pilocarpine 1.25% Ophthalmic Solution), and Xipere™ (Triamcinolone Acetonide Injections) – See Appendix O**

A. Introduction
B. Current Prior Authorization Criteria
C. Utilization of Various Special Formulations
D. Prior Authorization of Various Special Formulations
E. Product Summaries
F. College of Pharmacy Recommendations
G. Utilization Details of Various Special Formulations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

18. **U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix P**

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

19. **Future Business* (Upcoming Product and Class Reviews)**

A. Alzheimer's Disease Medications
B. Colorectal Cancer Medications
C. Testosterone Products
D. Various Systemic Antibiotics

*Future product and class reviews subject to change.

20. **Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.